SYDNEY, AUSTRALIA – Medidata has announced a partnership with one of Australia's leading biotech companies, Imugene, to use the Medidata Cloud solutions Rave EDC and Rave RTSM to support a major Phase II cancer study.
Imugene is a cancer immunotherapy company dedicated to developing gastric and breast cancer immunotherapies. The technology will allow Imugene to collect, aggregate and integrate a myriad of data sources, helping the company make informed choices during clinical trials. With the support of Medidata, the system improves access to patient information for analysis and extraction in real-time.
Medidata's platform solutions will improve operational efficiencies for Imugene and support the development of new immunotherapies. Rave RTSM is a 100% configurable randomization and trial supply management solution, with a single unified data store , which improves data quality, reduces risk and provides the flexibility needed for mid-study changes. Our innovative approach enables studies to start sooner and minimizes the potential impact of protocol design changes throughout the study lifecycle. Using Rave RTSM's Edit Live DesignTM feature simplifies the design and execution of adaptive trials.
"Immuno-oncology is one of the fastest advancing fields of cancer research and development in the world today, and we're excited to support Imugene in the development of these therapies," said Edwin Ng, vice president of field operations, APeJ. "Medidata's expertise and solutions will streamline Imugene's clinical trial process to significantly improve data capture throughout the complex patient journey. This will improve decision making for Imugene, thereby optimising clinical research outcomes."
"We're excited to partner with Medidata to enhance our research and offer better outcomes for patients through technology," said Dr. Anthony Good, vice president of clinical research at Imugene. "Nowadays, technology is becoming more important for the success of oncology clinical research and, with Medidata's solutions, we expect to develop more effective treatments for our patients by optimising drug development," he added.
About Medidata
Medidata is leading the digital transformation of life sciences with the world's most-used platform for clinical development, commercial and real-world data. Powered by artificial intelligence and delivered by #1 ranked industry experts, the Intelligent Platform for Life Sciences helps pharmaceutical, biotech, medical device companies and academic researchers accelerate value, minimize risk and optimize outcomes. Medidata serves more than 1,000 customers and partners worldwide and empowers more than 100,000 certified users every day to create hope for millions of patients. Discover the future of life sciences: www.mdsol.com
About Imugene
Imugene (ASX:IMU) is a clinical stage immuno-oncology company developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumours. Our unique platform technology seeks to harness the body's immune system to generate antibodies against tumours, potentially achieving a similar or greater effect than synthetically manufactured monoclonal antibody therapies. Our product pipeline includes multiple immunotherapy B-cell vaccine candidates aimed at treating a variety of cancers in combination with standard of care drugs and emerging immunotherapies. We are supported by a leading team of international cancer experts with extensive experience in developing new cancer therapies with many approved for sale and marketing for global markets.
Our vision is to help transform and improve the treatment of cancer and the lives of the millions of patients who need effective treatments. This vision is backed by a growing body of clinical evidence and peer-reviewed research. Imugene is well funded and resourced, to deliver on its commercial and clinical milestones. Together with leading specialists and medical professionals, we believe Imugene's immuno-oncology therapies will become a foundation treatment for cancer. Our goal is to ensure that Imugene and its shareholders are at the forefront of this rapidly growing global market.
